Calypso Biotech BV’s Competitors, Revenue, Number of Employees, Funding, Acquisitions & News

Calypso Biotech discovers and develops therapeutic monoclonal antibodies for the treatment of autoimmune diseases. Read more

Calypso Biotech discovers and develops therapeutic monoclonal antibodies for the treatment of autoimmune diseases. Read more

Alain Vicari's photo - Co-Founder & CEO of Calypso Biotech BV

Co-Founder & CEO

Alain Vicari

CEO Approval Rating

90/100

Founded:

2013

Status:

Est. Annual Revenue
Est. Employees

TOP COMPETITORS OR ALTERNATIVES

RANK

COMPANY

CEO

CEO RATING

EMPLOYEES

FUNDING

REVENUE

Missing a competitor? Contribute!

OSE Immunotherapeutics is a top competitor of Calypso Biotech BV. OSE Immunotherapeutics was founded in Nantes, Brittany} in 2012. OSE Immunotherapeutics competes in the Pharmaceuticals industry. Compared to Calypso Biotech BV, OSE Immunotherapeutics generates $2.7M more revenue.

argenx is Calypso Biotech BV's #2 competitor. argenx is headquartered in Breda, Noord-Brabant, and was founded in 2008. argenx operates in the Pharmaceuticals industry. argenx generates 296% the revenue of Calypso Biotech BV.

Capella Bioscience has been one of Calypso Biotech BV's top competitors. Capella Bioscience is a Private company that was founded in 2014 in London, England. Capella Bioscience operates in the Pharmaceuticals industry. Compared to Calypso Biotech BV, Capella Bioscience has 178 fewer employees.

Weigh-in!

Help the Owler community know more

Growth Score - 1/1

Is 181 a good estimate for Calypso Biotech BV's Employee count?

Acquisitions

No recent acquisitions found related to Calypso Biotech BV

Calypso Biotech BV Funding History

$22.6M

Since Calypso Biotech BV was founded in 2013, it has participated in 1 round of funding. In total Calypso Biotech BV has raised $22.6M. Calypso Biotech BV's funding round was on Feb 2019 for a total of $22.6M

ROUND

FUNDING DATE

AMOUNT

INVESTORS

Series A
Feb 2019
$22.6M

Gilde Healthcare

Since Calypso Biotech BV was founded in 2013, it has participated in 1 round of funding. In total Calypso Biotech BV has raised $22.6M. Calypso Biotech BV's funding round was on Feb 2019 for a total of $22.6M

Investments

No recent investments found related to Calypso Biotech BV

Calypso Biotech BV News

February 20, 2019Contract Pharma

AGC, Calypso Form Devt./Mfg. Deal

Enter agreement for process development and cGMP manufacture of CALY-002... See more »

Headquarters

Chemin des Aulx 14

Plan-les-Ouates, Geneva1228

41-22-552-3307

Driving Directions »

Trending Companies

Summary

ABOUT

Overview

Calypso Biotech discovers and develops therapeutic monoclonal antibodies for the treatment of autoimmune diseases. Calypso Biotech BV was founded in 2013. Calypso Biotech BV's headquarters is located in Plan-les-Ouates, Geneva, CH 1228. It has raised ...

CEO

Calypso Biotech BV's Co-Founder & CEO, Alain Vicari, currently has an approval rating of 90%. Calypso Biotech BV's primary competitors are OSE Immunotherapeutics, argenx & Capella Bioscience.

Website

calypsobiotech.com

Frequently Asked Questions about Calypso Biotech BV

  1. When was Calypso Biotech BV founded?

    Calypso Biotech BV was founded in 2013
  2. Who is Calypso Biotech BV's CEO?

    Calypso Biotech BV's CEO is Alain Vicari
  3. How much revenue does Calypso Biotech BV generate?

    Calypso Biotech BV generates $26.4M in revenue
  4. How much funding does Calypso Biotech BV have?

    Calypso Biotech BV has historically raised $22.6M in funding
  1. Where is Calypso Biotech BV's headquarters?

    Calypso Biotech BV's headquarters is in Plan-les-Ouates Geneva, CH
  2. How many employees does Calypso Biotech BV have?

    Calypso Biotech BV has 181 employees
  3. What sector does Calypso Biotech BV operate in?

    Calypso Biotech BV is in Biotechnology
  4. Who are Calypso Biotech BV's competitors?

    Calypso Biotech BV's top competitors are OSE Immunotherapeutics, argenx, Capella Bioscience